Search results
Results from the WOW.Com Content Network
Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), [a] is a type of chronic liver disease.This condition is diagnosed when there is excessive fat build-up in the liver (hepatic steatosis), and at least one metabolic risk factor.
ICD-10 is the 10th revision of the International Classification of Diseases (ICD), a medical classification list by the World Health Organization (WHO). It contains codes for diseases, signs and symptoms, abnormal findings, complaints, social circumstances, and external causes of injury or diseases. [1]
Steatohepatitis is a type of fatty liver disease, characterized by inflammation of the liver with concurrent fat accumulation in liver. Mere deposition of fat in the liver is termed steatosis , and together these constitute fatty liver changes.
The ICD-10 Clinical Modification (ICD-10-CM) is a set of diagnosis codes used in the United States of America. [1] It was developed by a component of the U.S. Department of Health and Human services, [ 2 ] as an adaption of the ICD-10 with authorization from the World Health Organization .
NAFLD affects about 30% of people in Western countries and 10% of people in Asia. [2] In the United States, rates are around 35% with about 7% having the severe form NASH. [1] NAFLD affects about 10% of children in the United States. [1] Recently the term Metabolic dysfunction-associated fatty liver disease (MAFLD) has been proposed to replace ...
Codes based on ICD-10 (WHO, 1992) structure for information exchange promoting interoperability. Uses a coding structure of five alphanumeric digits to link the two CCC System terminologies to each other and to map to other EHR/HIT systems. Designed for determining workload (productivity), resources (needs), outcomes (quality), and care costs.
National adaptations of the ICD-10 progressed to incorporate both clinical code (ICD-10-CM) and procedure code (ICD-10-PCS) with the revisions completed in 2003. In 2009, the US Centers for Medicare and Medicaid Services announced that it would begin using ICD-10 on April 1, 2010, with full compliance by all involved parties by 2013. [19]
Chronic hepatitis B management aims to control viral replication, which is correlated with progression of disease. [20] Seven drugs are approved in the United States: [ 20 ] Adefovir dipivoxil , a nucleotide analogue, has been used to supplement lamivudine in patients who develop resistance, but is no longer recommended as first-line therapy.